Cargando…
Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study
BACKGROUND: Active vitamin D is an effective treatment for secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients often complicated by hypercalcaemia and hyperphosphataemia. Treatment with paricalcitol, a selective vitamin D receptor activator, has shown benefits by adequately...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432442/ https://www.ncbi.nlm.nih.gov/pubmed/26019845 http://dx.doi.org/10.1093/ckj/sfs188 |
_version_ | 1782371483951038464 |
---|---|
author | Hadjiyannakos, Dimitrios Filiopoulos, Vassilis Trompouki, Sofia Sonikian, Makroui Karatzas, Ioannis Panagiotopoulos, Konstantinos Vlassopoulos, Dimosthenis |
author_facet | Hadjiyannakos, Dimitrios Filiopoulos, Vassilis Trompouki, Sofia Sonikian, Makroui Karatzas, Ioannis Panagiotopoulos, Konstantinos Vlassopoulos, Dimosthenis |
author_sort | Hadjiyannakos, Dimitrios |
collection | PubMed |
description | BACKGROUND: Active vitamin D is an effective treatment for secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients often complicated by hypercalcaemia and hyperphosphataemia. Treatment with paricalcitol, a selective vitamin D receptor activator, has shown benefits by adequately reducing parathyroid hormone (PTH) levels with minimal changes in serum calcium (Ca) and phosphorus (P). The purpose of this study is to present data on the use of oral paricalcitol in real-life clinical practice in patients with CKD stage 3–4 and SHPT. METHODS: We studied 43 patients, M/F: 25/18, median age: 74 years (47–87), CKD stage 3/4: 16/27, with SHPT, who were prescribed oral paricalcitol at recommended doses for 6 months. Monthly measurements of serum intact PTH (iPTH), Ca, P, alkaline phosphatase (ALP), haemoglobin, albumin (ALB), lipid profile, proteinuria and 24-h urine creatinine clearance were performed 3 months before and 6 months after treatment initiation. RESULTS: Paricalcitol induced a significant, early and sustained, through the end of follow-up period, decrease in iPTH and ALP levels and an increase in serum ALB. No significant increase in Ca and P levels as well as in Ca × P product was observed during the study period. No significant changes were found in protein excretion, kidney function and the other measured parameters between baseline and last evaluation. Paricalcitol final median dose was 5 μg/week ranging between 3 and 7 μg/week. CONCLUSIONS: In the context of real-life clinical practice, oral paricalcitol for 6 months is an effective, well-tolerated treatment of SHPT in CKD stage 3–4 with minimal effects on calcium and phosphorus metabolism. |
format | Online Article Text |
id | pubmed-4432442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44324422015-05-27 Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study Hadjiyannakos, Dimitrios Filiopoulos, Vassilis Trompouki, Sofia Sonikian, Makroui Karatzas, Ioannis Panagiotopoulos, Konstantinos Vlassopoulos, Dimosthenis Clin Kidney J Original Contributions BACKGROUND: Active vitamin D is an effective treatment for secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients often complicated by hypercalcaemia and hyperphosphataemia. Treatment with paricalcitol, a selective vitamin D receptor activator, has shown benefits by adequately reducing parathyroid hormone (PTH) levels with minimal changes in serum calcium (Ca) and phosphorus (P). The purpose of this study is to present data on the use of oral paricalcitol in real-life clinical practice in patients with CKD stage 3–4 and SHPT. METHODS: We studied 43 patients, M/F: 25/18, median age: 74 years (47–87), CKD stage 3/4: 16/27, with SHPT, who were prescribed oral paricalcitol at recommended doses for 6 months. Monthly measurements of serum intact PTH (iPTH), Ca, P, alkaline phosphatase (ALP), haemoglobin, albumin (ALB), lipid profile, proteinuria and 24-h urine creatinine clearance were performed 3 months before and 6 months after treatment initiation. RESULTS: Paricalcitol induced a significant, early and sustained, through the end of follow-up period, decrease in iPTH and ALP levels and an increase in serum ALB. No significant increase in Ca and P levels as well as in Ca × P product was observed during the study period. No significant changes were found in protein excretion, kidney function and the other measured parameters between baseline and last evaluation. Paricalcitol final median dose was 5 μg/week ranging between 3 and 7 μg/week. CONCLUSIONS: In the context of real-life clinical practice, oral paricalcitol for 6 months is an effective, well-tolerated treatment of SHPT in CKD stage 3–4 with minimal effects on calcium and phosphorus metabolism. Oxford University Press 2013-04 2013-02-05 /pmc/articles/PMC4432442/ /pubmed/26019845 http://dx.doi.org/10.1093/ckj/sfs188 Text en © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
spellingShingle | Original Contributions Hadjiyannakos, Dimitrios Filiopoulos, Vassilis Trompouki, Sofia Sonikian, Makroui Karatzas, Ioannis Panagiotopoulos, Konstantinos Vlassopoulos, Dimosthenis Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study |
title | Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study |
title_full | Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study |
title_fullStr | Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study |
title_full_unstemmed | Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study |
title_short | Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study |
title_sort | treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study |
topic | Original Contributions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432442/ https://www.ncbi.nlm.nih.gov/pubmed/26019845 http://dx.doi.org/10.1093/ckj/sfs188 |
work_keys_str_mv | AT hadjiyannakosdimitrios treatmentwithoralparicalcitolindailyclinicalpracticeforpatientswithchronickidneydiseasestage34apreliminarystudy AT filiopoulosvassilis treatmentwithoralparicalcitolindailyclinicalpracticeforpatientswithchronickidneydiseasestage34apreliminarystudy AT trompoukisofia treatmentwithoralparicalcitolindailyclinicalpracticeforpatientswithchronickidneydiseasestage34apreliminarystudy AT sonikianmakroui treatmentwithoralparicalcitolindailyclinicalpracticeforpatientswithchronickidneydiseasestage34apreliminarystudy AT karatzasioannis treatmentwithoralparicalcitolindailyclinicalpracticeforpatientswithchronickidneydiseasestage34apreliminarystudy AT panagiotopouloskonstantinos treatmentwithoralparicalcitolindailyclinicalpracticeforpatientswithchronickidneydiseasestage34apreliminarystudy AT vlassopoulosdimosthenis treatmentwithoralparicalcitolindailyclinicalpracticeforpatientswithchronickidneydiseasestage34apreliminarystudy |